Researchers explored the effects of a telemedicine visit on care in patients with T1D.
Intermittently scanned continuous glucose monitoring results in higher treatment satisfaction among adults with type 1 diabetes.
The American Diabetes Association (ADA) has published an update to their Standards of Medical Care in Diabetes for 2020.
A closed-loop insulin delivery system, also referred to as an artificial pancreas, was found to be more effective than sensor-augmented insulin pump therapy in patients with type 1 diabetes.
The FDA has expanded the indication for Fiasp (insulin aspart injection; Novo Nordisk) 100 Units/mL to include use in insulin infusion pumps to improve glycemic control in adults with type 1 or type 2 diabetes.
There were no clear benefits of using faster insulin aspart in closed-loop insulin therapy and the closed-loop algorithm was better adjusted to the use of standard insulin aspart.
Medical devices that can connect to the internet might be at risk for hacking, the U.S. Food and Drug Administration warned Tuesday.
Colophonium, a fast-acting adhesive and known sensitizing allergen, may cause dermatologic reactions in children using devices to manage diabetes.
Highest rates reported among preschoolers, children, and adolescents aged younger than 15 years
Real-world usage of an implantable continuous glucose monitoring system shows promise for improved glycemic control, sensor accuracy, and safety.
The FDA has granted 510(k) market clearance to the OneDraw A1C Test system, which monitors HbA1c levels in individuals with diabetes for long-term glucose control.